1-800-526-8630
1 of 5
FEATURED COMPANIES
- Akshaya Bio Inc.
- Altravax, Inc.
- EpiVax, Inc.
- MORE
Equine Encephalitis - Pipeline Review, H1 2016
Summary
‘Equine Encephalitis - Pipeline Review, H1 2016’, provides an overview of the Equine Encephalitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects.
Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Equine Encephalitis
- The report reviews pipeline therapeutics for Equine Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Equine Encephalitis therapeutics and enlists all their major and minor projects
- The report assesses Equine Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Equine Encephalitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Summary
‘Equine Encephalitis - Pipeline Review, H1 2016’, provides an overview of the Equine Encephalitis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Equine Encephalitis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Equine Encephalitis and features dormant and discontinued projects.
Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Equine Encephalitis
- The report reviews pipeline therapeutics for Equine Encephalitis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Equine Encephalitis therapeutics and enlists all their major and minor projects
- The report assesses Equine Encephalitis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Equine Encephalitis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Equine Encephalitis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Equine Encephalitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Note: Product cover images may vary from those shown
2 of 5
FEATURED COMPANIES
- Akshaya Bio Inc.
- Altravax, Inc.
- EpiVax, Inc.
- MORE
List of Tables
List of Figures
Introduction
Report Coverage
Equine Encephalitis Overview
Therapeutics Development
Pipeline Products for Equine Encephalitis - Overview
Pipeline Products for Equine Encephalitis - Comparative Analysis
Equine Encephalitis - Therapeutics under Development by Companies
Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
Equine Encephalitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Equine Encephalitis - Products under Development by Companies
Equine Encephalitis - Products under Investigation by Universities/Institutes
Equine Encephalitis - Companies Involved in Therapeutics Development
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Equine Encephalitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DEF-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TSI-GSD-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Western Equine Encephalitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Westrern Equine Encephalitis Virus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Equine Encephalitis - Recent Pipeline Updates
Equine Encephalitis - Dormant Projects
Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Equine Encephalitis, H1 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Equine Encephalitis - Pipeline by Akshaya Bio Inc., H1 2016
Equine Encephalitis - Pipeline by Altravax, Inc., H1 2016
Equine Encephalitis - Pipeline by EpiVax, Inc., H1 2016
Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H1 2016
Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Equine Encephalitis Therapeutics - Recent Pipeline Updates, H1 2016
Equine Encephalitis - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Equine Encephalitis, H1 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
List of Figures
Introduction
Report Coverage
Equine Encephalitis Overview
Therapeutics Development
Pipeline Products for Equine Encephalitis - Overview
Pipeline Products for Equine Encephalitis - Comparative Analysis
Equine Encephalitis - Therapeutics under Development by Companies
Equine Encephalitis - Therapeutics under Investigation by Universities/Institutes
Equine Encephalitis - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Equine Encephalitis - Products under Development by Companies
Equine Encephalitis - Products under Investigation by Universities/Institutes
Equine Encephalitis - Companies Involved in Therapeutics Development
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Equine Encephalitis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
DEF-201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
imatinib mesylate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Monoclonal Antibody for Venezuelan Equine Encephalitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
nilotinib - Drug Profile
Product Description
Mechanism of Action
R&D Progress
TSI-GSD-104 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Vaccine for Western Equine Encephalitis - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Venezuelan equine encephalitis vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
verdinexor - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Westrern Equine Encephalitis Virus Vaccine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Equine Encephalitis - Recent Pipeline Updates
Equine Encephalitis - Dormant Projects
Equine Encephalitis - Product Development Milestones
Featured News & Press Releases
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Dec 09, 2015: Profectus BioSciences Receives $4.6 Million DOD Grant to Develop Vaccine for Western, Eastern, and Venezuelan Equine Encephalitis Viruses
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Equine Encephalitis, H1 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Development, H1 2016
Products under Development by Companies, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Equine Encephalitis - Pipeline by Akshaya Bio Inc., H1 2016
Equine Encephalitis - Pipeline by Altravax, Inc., H1 2016
Equine Encephalitis - Pipeline by EpiVax, Inc., H1 2016
Equine Encephalitis - Pipeline by Integrated BioTherapeutics, Inc., H1 2016
Equine Encephalitis - Pipeline by Karyopharm Therapeutics, Inc., H1 2016
Equine Encephalitis - Pipeline by Profectus BioSciences, Inc., H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Stage and Target, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Equine Encephalitis Therapeutics - Recent Pipeline Updates, H1 2016
Equine Encephalitis - Dormant Projects, H1 2016
List of Figures
Number of Products under Development for Equine Encephalitis, H1 2016
Number of Products under Development for Equine Encephalitis - Comparative Analysis, H1 2016
Number of Products under Development by Companies, H1 2016
Number of Products under Investigation by Universities/Institutes, H1 2016
Comparative Analysis by Clinical Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy Products, H1 2016
Number of Products by Targets, H1 2016
Number of Products by Stage and Targets, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5
LOADING...
4 of 5
Akshaya Bio Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Altravax, Inc.
EpiVax, Inc.
Integrated BioTherapeutics, Inc.
Karyopharm Therapeutics, Inc.
Profectus BioSciences, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
